Objective: The seventh edition of the TNM Classification of Malignant Tumours was published in 2009. The present study was conducted to investigate the clinicopathological features of p-T1aN0M0 non-small-cell lung cancer, which is the earliest stage defined in the new tumor, node, metastasis (TNM) classification, in relation to patient prognosis. Methods: We retrospectively studied 162 patients, who underwent surgical resection at our institution for p-T1aN0M0 non-small-cell lung cancer, as re-categorized in the seventh TNM classification. Univariate and multivariate analyses of disease-free survival were performed. Results: The mean tumor size was 13.2 AE 4.7 mm. The maximum tumor diameter was >10 mm in 104 cases (64.6%), and 10 mm in 58 (35.4%). The median follow-up period was 44.5 months. Univariate analysis showed that the 5-year disease-free survival rate of patients with and without preoperative serum carcinoembryonic antigen elevation was 50.8% and 95.1% (P < 0.0001), respectively, that of patients with and without blood vessel or lymphatic invasion was 40.0% and 95.8% (positive vs negative, P < 0.0001), respectively, and that of patients aged !70 years and <70 years was 86.8% and 96.1% (P = 0.014), respectively. Multivariate analysis including these three clinicopathologic factors demonstrated that preoperative elevation of the carcinoembryonic antigen level and blood vessel or lymphatic invasion were independent prognostic factors. Conclusion: In patients with p-T1aN0M0 non-small-cell lung cancer, an elevated preoperative carcinoembryonic antigen level and blood vessel or lymphatic invasion tend to affect prognosis to a greater degree than tumor size. Therefore, the efficacy of adjuvant chemotherapy for these patients should be evaluated in clinical trials. #
Introduction
The seventh edition of the TNM Classification of Malignant Tumours was published in 2009. In this new tumor, node, metastasis (TNM) classification, proposed by the International Association for the Study of Lung Cancer (IASLC), tumors having a maximum dimension of 2 cm or smaller, without pleural invasion, should be designated T1a, whereas those that are larger than 2 cm but 3 cm or smaller should be designated T1b. The optimal cut-off points for tumor size in the new staging were determined by using 'a running log-rank test' [1] . In an analysis of prognosis based on the T classification, Kameyama et al. demonstrated clear differences between T1a and T1b patients [2] . Therefore, it would be expected that for non-small-cell lung cancer (NSCLC), p-T1aN0M0 cases, which represent the very earliest stage, would have the best prognosis. In clinical practice, however, some patients even in this group show relapse after complete surgical resection. To decide the indicator for detection of this subgroup is very important.
Several studies have demonstrated that p-Stage I A NSCLC, as defined on the basis of the sixth TNM classification, can be subdivided according to indicators of poor prognosis such as smoking history, serum level of carcinoembryonic antigen (CEA), surgical procedure, tumor size, and blood vessel or lymphatic invasion [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] .
In addition, several studies have reported that there are clear differences in prognosis based on tumor size in patients with p-Stage I disease as defined by the sixth TNM classification [3] [4] [5] [6] . However, it is unclear whether this applies generally to all cases in which the maximum tumor dimension is 2 cm or less.
In the present study, we retrospectively analyzed clinicopathological factors in p-T1aN0M0 NSCLC, as defined by the new TNM staging, in relation to prognosis in patients treated at a single institution. 18 F]fluoro-2-deoxy-D-glucose (FDG-PET), with reference to the sixth TNM classification of 1997. All patients were then reclassified by reference to the seventh edition of the TNM classification. Of these patients, 162 were proven to be p-T1aN0M0 pathologically, based on the seventh edition. Patients with pathologically proven synchronous or metachronous multiple lung cancers were excluded.
For the 162 selected cases, we reviewed the clinical features including patient age and gender, preoperative serum CEA level, and tumor localization, and also perioperative data including the surgical procedure employed, histopathological type, presence of blood vessel or lymphatic invasion, and the rates of disease-free survival (DFS) and overall survival (OS). The location of the carcinoma was recorded from the preoperative evaluation and adjusted according to intra-operative findings, if necessary. In agreement with institutional policy, lobectomy or bilobectomy with systematic lymphadenectomy was typically performed. In patients with peripheral lesions, or with poor pulmonary function, segmentectomy or wedge resection with mediastinal or hilar lymph node sampling was performed for N-staging. Patients who underwent lobectomy or bilobectomy were defined as the 'standard resection' group, and those who underwent segmentectomy or wedge resection as the 'limited resection' group. Only six patients underwent adjuvant chemotherapy with oral uracil-tegafur.
Follow-up information was obtained from office visits or telephone contact with patients, relatives, or physicians. The follow-up schedule consisted of a clinic visit every 3 months during the first 2 years, every 3-6 months from the second to the fifth year, and at 1-year intervals thereafter. The follow-up procedures included physical examination, chest roentgenography, and determination of serum tumor marker levels. CT scans of the brain, chest, and abdomen, and systemic bone scintigraphy, were performed every year. PET was introduced at our institution in 2002, and thereafter used for screening or confirmation of recurrences.
Recurrence was diagnosed by physical examination and diagnostic imaging, with or without histological confirmation. Elevation of serum tumor marker levels alone was not considered definitive of recurrence. The date of recurrence was defined as the date when the attending physician recognized the presence of recurrent disease.
The histologic type of the tumor was determined on the basis of the World Health Organization classification. Blood vessel or lymphatic invasion in the primary lesion was evaluated by hematoxylin-eosin and Elastica van Gieson staining. All histologic preparations were evaluated by pathologists at our hospital, on the basis of common consensus.
Blood samples for CEA measurement were obtained within 1 month before surgery. Preoperative CEA levels were assessed using enzyme-linked immunosorbent assay (ELISA) kits, based on a cut-off value of 5.0 ng ml À1 . DFS or OS rate was assessed by the Kaplan-Meier method, and any differences were evaluated using the log-rank test for discrete data. Results were considered significant at P values of <0.05. To determine independent prognostic factors, multivariate analysis was conducted using the Cox proportional hazards model (Wald stepwise backward elimination method). Cancer-related death was defined as the terminal event. Calculations and statistical tests were performed using the Statview 5.0 software package (SAS Institute, Inc, Cary, NC, USA).
Results

Clinical features
The characteristics and clinical features of all the patients are shown in Table 1 . There were 86 men (53.1%) and 76 women (46.9%), ranging in age from 26 to 88 years (mean, 66.2 AE 12.4 years). The preoperative serum CEA level was elevated in 15 patients (9.3%). It was not elevated in 140 patients (86.4%) and undetectable in seven (4.3%).
Surgical procedure
Standard resection with systemic lymphadenectomy was performed in 120 patients (74.0%), and limited resection with lymph node sampling was performed in 42 cases (26.0%). The contents of surgical procedure are demonstrated in Table 1 . The localization of tumors is shown in Table 1 .
Histopathological type and pathological stage
Mean tumor size was 13.2 AE 4.7 mm, ranging from 3 to 20 mm. The maximum tumor diameter exceeded 10 mm in 104 cases (64.6%) and was 10 mm or less in 58 (35.4%). The 
Long-term survival
The median follow-up period was 44.5 months, and the 5-year DFS rate for the cases overall was 91.7%. During the follow-up period, radiographic examinations in 10 patients revealed recurrence, and this was proven pathologically in one case. Distant metastasis was detected in four patients, comprising of bone metastasis in two and pulmonary metastasis in two. Local recurrence was detected in five patients, comprising mediastinal or hilar lymph node metastasis in four, and recurrence at the resected stump and carcinomatous pleuritis in one. Both distant metastasis and local recurrence were detected simultaneously in one patient with bone metastasis, and mediastinal and hilar lymph node metastasis. In the standard resection group, three patients had local recurrence, three had distant metastasis, and one had both. In the limited resection group, two patients had local recurrence and one had distant metastasis. In addition, 5 (33%) of the 15 patients in the group with CEA elevation had recurrence. Recurrence was also observed in 5 (38.5%) of 13 patients in the group with positive blood vessel or lymphatic invasion, and in 8 (10.3%) of 78 patients aged >70 years.
The 5-year OS in patients overall was 98.4%. Nine patients died during the study period, and only two of the deaths were cancer related.
Univariate/multivariate prognostic analyses
The results of univariate analysis based on the 5-year DFS rate are shown in Table 2 . Clinically significant features shown to be correlated with prognosis by univariate analysis were preoperative serum CEA level (normal vs elevated, P < 0.0001), vascular or lymphatic invasion (positive vs negative, P < 0.0001), and patient age (<70 years vs !70 years, P = 0.014). DFS curves for preoperative serum CEA level and blood vessel or lymphatic invasion are shown in Figs. 1 and 2 , respectively. The 5-year DFS rates for patients with and without preoperative serum CEA elevation were 50.8% and 95.1%, respectively, and those for patients with and without blood vessel or lymphatic invasion were 40.0% and 95.8%, respectively. The 5-year DFS rates for patients aged <70 years and !70 years were 96.1% and 86.8%, respectively. Other features, including gender (male vs female, P = 0.17), surgical procedure (standard resection vs limited resection, P = 0.58), tumor size (>10 mm vs 10 mm, P = 0.19), and pathological type (Adenocarcinoma vs Non-Adenocarcinoma, P = 0.44), were not significant survival predictors in the present series.
The three clinicopathologic factors, age, preoperative serum CEA level, and blood vessel or lymphatic invasion, were included as covariates for multivariate analysis. In this setting, preoperative serum CEA level and blood vessel or lymphatic invasion were identified as independent predictors (Table 3 ). In terms of 5-year OS, only the preoperative serum CEA level was demonstrated to be clinically significant by univariate analysis (P = 0.0247). [ [ ( ) T D $ F I G ] 
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Discussion
The purpose of the present study was to investigate independent prognostic factors in patients who had undergone complete surgical resection of p-T1aN0M0 NSCLC, defined on the basis of the seventh TNM classification. Our results clearly demonstrated that blood vessel or lymphatic invasion and elevation of the preoperative CEA level were factors indicative of poor prognosis in this patient cohort.
Many previous studies have demonstrated that elevation of the preoperative CEA level is a negative prognostic indicator in patients, who have undergone surgical resection of lung cancer [7] [8] [9] . Okada et al. reported that the 5-year survival rates for c-Stage I NSCLC patients with normal and high preoperative CEA levels were 75.2% and 53.8%, respectively, and that the difference was significant [8] . Although we focused on pathological staging, the 5-year DFS rate for the group with an elevated preoperative CEA level was 50.8%, which was also poor. Our data also revealed that an elevated preoperative CEA level was a possibly negative prognostic factor, even in patients classified as p-T1aN0M0 on the basis of the seventh TNM classification. Okada et al. categorized patients into three groups according to the shift in the CEA level resulting from surgery: continuously normal (N group), continuously high (HH group), or a return to the normal range (HN group), and patients in the HH group with Stage I lung cancer had a 5-year survival rate of 48.6%. They considered this to be surprising, and we concur. Matsuguma et al. also categorized p-Stage I A NSCLC patients into three groups on the same basis, and showed that the 5-year survival rate in the HH group was 50.7% [9] . Although the perioperative CEA level is currently not included in the new TNM classification, we suggest that for patients with an increased CEA level, adjuvant treatment should be considered.
As well as elevation of the preoperative CEA level, several reports have maintained that vessel invasion is a negative prognostic factor in patients with p-Stage I A NSCLC as defined by the sixth TNM classification [10] [11] [12] . Tsuchiya et al. demonstrated that the 5-year survival rate of such patients was 71.8%, and it was significantly poorer in comparison with patients lacking vessel invasion [10] . In addition, they showed that distant metastasis was more frequent in the vessel invasion group. Similarly, our study demonstrated high rates of recurrence in patients with blood vessel or lymphatic invasion and in patients with an elevated CEA level (38.5% and 33.3%, respectively), while the rate of recurrence in patients overall was 6.2% (10 of 162 patients). Miyoshi et al. reported that intratumoral vessel invasion, comprising blood vessel invasion and lymphatic invasion, was a negative prognostic factor in p-Stage I A NSCLC patients [11] . Although most previous studies taking into account blood vessel invasion and lymphatic invasion dealt with each factor separately, Miyoshi et al. maintained that this separation was not important because of the limited ability to differentiate the two on the basis of hematoxylin-eosin and Elastica van Gieson staining. Therefore, they treated blood vessel invasion and lymphatic vessel invasion together as intratumoral vessel invasion, as was the case in the present study.
With regard to other prognostic factors in early-stage NSCLC patients, several authors have reported the significance of positive intra-operative pleural lavage cytology [13] [14] [15] . Nakagawa et al. reported that positive pleural lavage cytology in p-Stage I NSCLC patients was an independent prognostic factor, whereas no prognostic significance of this parameter was seen for p-Stage IV [13] . In addition, they demonstrated the prognostic significance of positive pleural lavage cytology in patients without pleural invasion. Therefore, even in s-T1aN0M0 patients, who have no evident pleural invasion intra-operatively, pleural lavage cytology may be of prognostic significance. Like the preoperative CEA level, pleural lavage and blood vessel or lymphatic invasion are not included in the seventh TNM classification. Although the new TNM staging is an essential anatomic system, these biological factors need to be taken into consideration for assigning optimal treatment to patients with p-T1aN0M0 NSCLC.
In the present study, limited resections were performed in 42 patients with peripheral lesions or poor pulmonary function. Two of these patients suffered local recurrence. Although we consider this result acceptable, it does not necessarily indicate that NSCLC patients with tumors 2 cm or less in diameter without pleural invasion are good candidates for limited resection because these small peripheral tumors are sometimes associated with intrathoracic lymph node involvement [16, 17] . A prospective randomized phase III study of limited resection for peripheral lung cancers with a diameter of 2 cm or less is currently planned by the Japan Clinical Oncology Group, although the limited resection referred to in this context is not wedge resection but segmentectomy with hilar and mediastinal lymph node dissection [18] . The results of this study may represent better criteria for limited resection in the future.
Several previous studies have demonstrated that adjuvant chemotherapy can improve the outcome of patients with NSCLC [19] [20] [21] . In Japan, oral uracil-tegafur, as reported by Kato et al., has been frequently administered as adjuvant chemotherapy for patients with p-Stage I B NSCLC as defined by the sixth TNM classification [21] . On the other hand, a meta-analysis by the Lung Adjuvant Cisplastin Evaluation (LACE) Collaborative group revealed that adjuvant chemotherapy worsened the prognosis of p-Stage I A NSCLC patients (hazard ratio (HR): 1.40, 95% confidence interval (CI): 0.95-2.06) [22] . This might have been due to the deleterious effects of toxicities, which outweighed any Christian et al. reported that tumor size was an independent prognostic factor among patients who had undergone surgical resection of stage I NSCLC, with an appropriate cut-off value of 20 mm, and a similar conclusion was reached by Birim et al. [5, 6] . On the other hand, Gajra et al. and Lyons et al. demonstrated that if the cut-off value was 15 mm, there was a significant difference in overall survival between the two groups [3, 4] . By contrast, our study demonstrated no significant difference in prognosis between the >10 mm group and the 10 mm group. In the seventh TNM classification, the T-factor was subdivided more precisely compared with the sixth TNM classification, based on previous reports. However, our result indicated that subdivision of the T-factor more precisely in the 20 mm group had no effect on DFS, although improved imaging techniques can facilitate more precise T-factor subdivision. The present data for pT1aN0M0 patients indicated that, as biological factors, elevation of the CEA level and blood vessel or lymphatic invasion had a greater effect on prognosis than tumor size. Therefore, clinical trials should be conducted to assess the efficacy of adjuvant chemotherapy in p-T1aN0M0 patients with an elevated CEA level and blood vessel or lymphatic invasion, even though such patients are at the earliest disease stage according to the seventh TNM classification.
